share_log

Cerus (NASDAQ:CERS) Reaches New 52-Week Low at $3.42

Cerus (NASDAQ:CERS) Reaches New 52-Week Low at $3.42

CERUS(納斯達克:CERS)跌至3.42美元的52周新低
Financial News Live ·  2022/09/27 14:52

Cerus Co. (NASDAQ:CERS – Get Rating) shares hit a new 52-week low during trading on Tuesday . The company traded as low as $3.42 and last traded at $3.42, with a volume of 30076 shares. The stock had previously closed at $3.47.

賽樂斯公司(納斯達克代碼:CERS-GET Rating)的股價週二創下52周新低。該公司股價最低跌至3.42美元,最新報3.42美元,成交量為30076股。該股此前收盤價為3.47美元。

Cerus Trading Down 1.7 %

Cerus交易下跌1.7%

The stock has a market cap of $603.88 million, a P/E ratio of -14.46 and a beta of 1.14. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.08 and a quick ratio of 1.73. The business's 50 day simple moving average is $4.68 and its 200 day simple moving average is $4.98.

該股市值為6.0388億美元,市盈率為-14.46,貝塔係數為1.14。該公司的債務權益比為0.53,流動比率為2.08,速動比率為1.73。該業務的50日簡單移動均線切入位為4.68美元,200日簡單移動均線切入位為4.98美元。

Get
到達
Cerus
穀神星
alerts:
警報:

Insider Activity

內幕活動

In other news, insider Richard J. Benjamin sold 10,000 shares of Cerus stock in a transaction that occurred on Tuesday, August 9th. The shares were sold at an average price of $5.12, for a total value of $51,200.00. Following the completion of the transaction, the insider now owns 172,665 shares in the company, valued at $884,044.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 7.33% of the stock is currently owned by corporate insiders.

在其他新聞方面,內部人士理查德·J·本傑明在8月9日星期二的一筆交易中出售了10,000股Cerus股票。這些股票的平均價格為5.12美元,總價值為51,200.00美元。交易完成後,這位內部人士現在擁有該公司172,665股股票,價值884,044.80美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,該文件可通過此超鏈接。7.33%的股份目前由企業內部人士持有。

Institutional Inflows and Outflows

機構資金流入和流出

A number of institutional investors have recently modified their holdings of the company. Legal & General Group Plc raised its stake in shares of Cerus by 9.9% in the second quarter. Legal & General Group Plc now owns 328,358 shares of the biotechnology company's stock valued at $1,737,000 after acquiring an additional 29,597 shares during the last quarter. ExodusPoint Capital Management LP raised its position in Cerus by 3.8% in the 2nd quarter. ExodusPoint Capital Management LP now owns 233,339 shares of the biotechnology company's stock worth $1,234,000 after purchasing an additional 8,516 shares during the last quarter. Walleye Capital LLC bought a new position in Cerus in the 2nd quarter worth approximately $154,000. Goldman Sachs Group Inc. raised its position in Cerus by 102.4% in the 2nd quarter. Goldman Sachs Group Inc. now owns 863,845 shares of the biotechnology company's stock worth $4,570,000 after purchasing an additional 437,101 shares during the last quarter. Finally, Tamarack Advisers LP raised its position in Cerus by 21.2% in the 2nd quarter. Tamarack Advisers LP now owns 2,000,000 shares of the biotechnology company's stock worth $10,580,000 after purchasing an additional 350,000 shares during the last quarter. Institutional investors own 84.72% of the company's stock.
多家機構投資者最近調整了對該公司的持股。Legal&General Group Plc在第二季度增持了Cerus 9.9%的股份。Legal&General Group Plc在上個季度增持了29,597股後,現在擁有這家生物技術公司328,358股股票,價值1,737,000美元。ExodusPoint Capital Management LP在第二季度將其在Cerus的頭寸提高了3.8%。ExodusPoint Capital Management LP現在擁有這家生物技術公司233,339股股票,價值1,234,000美元,此前在上個季度又購買了8,516股。Walleye Capital LLC在第二季度購買了Cerus的一個新頭寸,價值約15.4萬美元。高盛股份有限公司在第二季度將其在Cerus的持倉提高了102.4%。高盛股份有限公司在上個季度增持了437,101股後,目前持有這家生物技術公司863,845股股票,價值4,57萬美元。最後,Tamarack Advisers LP在第二季度將其在Cerus的頭寸提高了21.2%。Tamarack Advisers LP現在擁有200萬股這家生物技術公司的股票,價值1058萬美元,此前在上個季度又購買了35萬股。機構投資者持有該公司84.72%的股票。

About Cerus

關於Cerus

(Get Rating)

(獲取評級)

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

Cerus公司是一家生物醫藥產品公司。該公司專注於開發攔截血液系統並將其商業化,以增強血液安全。其攔截血液系統,這是一項控制生物複製的專利技術,旨在減少用於輸血的捐獻血液成分中的血源性病原體。

Further Reading

進一步閲讀

  • Get a free copy of the StockNews.com research report on Cerus (CERS)
  • Build A Better Tech Portfolio With Jabil Inc.
  • Is There Value In These Growth Stocks?
  • Autodesk Is A Mature Company Still Acting Like A Growth Stock
  • MarketBeat Podcast, 3 Stocks to Watch Newmont Mining, Walmart, AMC
  • Is the Market Overreacting with Shopify Stock?
  • 免費獲取StockNews.com關於Cerus的研究報告(CERS)
  • 與捷普公司一起打造更好的技術產品組合。
  • 這些成長型股票有價值嗎?
  • 歐特克是一家成熟的公司,仍是一隻成長型股票
  • MarketBeat Podcast,3只股票關注紐蒙特礦業、沃爾瑪、AMC
  • 市場是否對Shopify Stock反應過度?

Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.

接受《Cerus Daily》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Cerus和相關公司的最新新聞和分析師評級的每日簡要摘要。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論